Nov 17, 2005

Conventional disease-modifying antirheumatic drugs in early arthritis

Rheumatic Diseases Clinics of North America
T SokkaT Möttönen

Abstract

This article reviews the use of conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of early rheumatoid arthritis (RA). The Finnish early RA cohorts are used as examples of how early and active treatment strategies have improved over time with increasing variety of available DMARDs. Therapy goals of early RA include remission to prevent severe long-term outcomes of RA. Remission can be achieved in a third of patients with early RA using a combination of conventional DMARDs, including methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone. Of patients with early RA, 20% to 30% do not improve enough with conventional treatments and should be identified at early phases to consider institution of biologic agents.

  • References50
  • Citations9

References

  • References50
  • Citations9

Citations

Mentioned in this Paper

Larsen Syndrome
Antirheumatic Drugs, Disease-Modifying
Penicillamine
Glucocorticoid inhalants for obstructive airway disease
Hydroxychloroquine
Cyclosporine
Transcription Initiation
Prednisolone
Corticosteroids, topical for treatment of hemorrhoids and anal fissures
Glucocorticoids, Systemic

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.